Following a series of delays in care provision at a hospital, a son shared his mother’s ordeal, detailing how she encountered prolonged waiting times that fell short of established standards for patient care.
The Parliamentary and Health Service Ombudsman directed the Mid and South Essex NHS Foundation Trust (MSE) to apologize to the family of a 67-year-old woman identified as Mrs S due to deficiencies in her care and management of a cancer diagnosis.
Tragically, Mrs S, a retired history teacher and mother of two from Chelmsford, Essex, passed away in 2023 as a result of delays in receiving a timely diagnosis and subsequent treatment. Despite seeking medical attention for abdominal discomfort in January 2023 and being referred to the MSE, her diagnosis and treatment were significantly delayed. She was deemed unfit for treatment by the time the trust became involved. Known for her active role in the community through volunteering, choir participation, and tennis, Mrs S underwent a CT scan on February 16, a biopsy on March 15, and was diagnosed with ovarian cancer on March 21. Although informed that she was beyond cure, chemotherapy could prolong her life; however, treatment was postponed to a point where it was no longer viable. The Ombudsman highlighted that had the MSE trust adhered to waiting time guidelines, treatment should have commenced on April 3, potentially enabling Mrs S to undergo chemotherapy.
Notably, Mrs S experienced a 49-day delay in diagnosis and had to wait an additional 81 days for treatment, both of which markedly exceeded the NHS standards applicable at the time.
As per the Ombudsman’s findings, a cancer patient like Mrs S should have received a diagnosis within 28 days of referral and initiated treatment within 62 days, both of which were not met in her case. She endured a 75% delay in diagnosis and a 31% extension in treatment initiation, ultimately missing the window for effective intervention.
Subsequent to her son lodging a complaint regarding his mother’s care, the hospital trust acknowledged improvements in cancer waitlist times but noted a decline in meeting treatment targets. Data revealed a decrease in the percentage of cancer patients receiving treatment within 62 days, dropping from 47% in February 2023 to 46% by July 2025, with the latest recorded figure in October 2025 standing at 47%.
The Ombudsman’s investigation highlighted the emotional distress caused to Mrs S and her family by the MSE trust’s failures, prompting a recommendation for a review of waiting times and implementation of necessary enhancements.
Expressing ongoing anguish, Mrs S’s son shared recollections of his mother’s premature discharge from the hospital without adequate support shortly before her demise, emphasizing the series of delays and frustrations they encountered throughout the ordeal.
Reflecting on the situation, he lamented the prolonged diagnostic and treatment processes, underscoring the missed opportunities for improving his mother’s quality of life and extending their time together.
The Ombudsman advocated for the trust to scrutinize its performance against national benchmarks and devise a comprehensive strategy for enhancement, a recommendation that the trust committed to executing. It plans to introduce new technology to optimize resource allocation and bolster capacity for cancer appointments, aiming to align wait times with national guidelines and prevent similar incidents from reoccurring.
Chief Executive Dawn Scrafield of the MSE NHS Foundation Trust conveyed regret over the treatment delay experienced by Mrs S and her family, attributing it to increased demand and outlining efforts to streamline diagnostic services and treatment processes in collaboration with healthcare partners.
Emphasizing cancer care as a top priority, Scrafield noted early signs of reduced wait times in specific cancer areas as the trust implements additional clinics and refines theater scheduling to expedite patient care.
At Reach and its affiliates, user data is utilized to enhance site experience, analyze usage patterns, and tailor personalized advertisements. Opt-out options are available via the “Do Not Sell or Share my Data” button on the webpage, with user consent presumed through website utilization, aligning with the Privacy Notice and Terms and Conditions outlined.